ACIU
LLY
Lilly writes another check
AC Immune says it amended its 2018 license-and-collaboration deal with Eli Lilly to expand work on Tau aggregation inhibitor small molecules. Translation: the two companies are not just keeping the relationship alive — they’re giving it a bigger playground.
Why investors care
The real story here is optionality. AC Immune’s Morphomer platform is built to design small molecules that can get into the brain orally and go after pathological Tau, a nasty player in Alzheimer’s and other neurodegenerative diseases. If you’re holding the stock, this is the kind of update that says a Big Pharma heavyweight still sees enough promise to keep funding the experiment.
What changes now
Under the amended agreement, the collaboration now covers:
- new lead Tau Morphomer candidates
- potential back-up compounds
- IND-enabling studies expected to start in the first half of 2026
That doesn’t mean a miracle cure is around the corner. But it does mean the program is moving from “interesting science project” closer to “let’s see if this can actually become a drug.”
Big picture
For a clinical-stage biotech, having Lilly stay engaged is not nothing. It can help de-risk the platform in the eyes of investors, even if the road to meaningful human data still looks long and twisty.